Michael Rezak, MD, PhD: April 11, 2017

Parkinson’s Disease is Second Most Common Neurodegenerative Disorder After Alzheimer’s

April is National Parkinson’s Awareness Month

MICHAEL REZAK, MD, PhD, Neurology
Medical Director of the Movement Disorders Center
Northwestern Medicine Central DuPage Hospital

 

Background:
Approximately one million people in the United States suffer from Parkinson’s disease (PD) – more than multiple sclerosis, Lou Gehrig’s disease, muscular dystrophy and myasthenia gravis combined.  As the population ages, epidemiologists believe the number of people with PD will at least double by 2030.

Currently, there is no cure for PD. While there have been advances in treatment and care, the cause remains unknown. Because symptoms may take years to develop, patients may live for years with the disease before diagnosis.

The Northwestern Medicine Central DuPage Hospital Movement Disorders and Neurodegenerative Diseases Center is focused on research, both in the basic science laboratory as well as with clinical trials, to advance the diagnosis, treatment and prevention of Parkinson’s disease.

Medical Director Michael Rezak, MD, is available for live interviews to discuss the latest research, including Northwestern Medicine’s work on potential diagnostic tools using biomarkers to confirm Parkinson’s disease, and allow the early identification of patients in the pre-symptomatic phase of the illness.

FOR MORE IMFORMATION VISIT:  Northwestern Medical’s – Parkinsons Page

MORE ABOUT DR. MICHAEL REZAK:

Michael Rezak, MD, PhD, neurology, is the medical director of the Movement Disorders Center at Northwestern Medicine Central DuPage Hospital.  He also serves as the medical director of the American Parkinson’s Disease Association (APDA) Midwest Information. He is a member of the Scientific Advisory Board of the Chicago Chapter of the Dystonia Medical Research Association and is on the faculty for Medtronic (Deep Brain Stimulation). Dr. Rezak is active in research in Parkinson’s disease (PD) and currently serves as principal investigator in several trials, including the development of valid markers and risk factors to identify patients in the preclinical phase of PD (funded by the Parkinson’s Disease Research Society); and has been involved in the NIH-funded CORE PD Consortium on Risk for Early Onset Parkinson’s Disease and the Parkinson’s Disease Collaborative Study of Genetic Linkage (PROGENT) studies. Dr. Rezak received his PhD in neuroanatomy from the University of Illinois Medical Center. He received his medical degree from Loyola University Stritch school of Medicine. He completed his neurological training at Yale University school of Medicine.

Speak Your Mind

*